Q&A with FDA

September 25, 2023by Todd Eury

“Q&A with FDA” provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of the most commonly asked questions received by FDA. Perhaps you have had the same questions but never asked.

CURE ID is an internet-based repository that allows the global community to report novel uses of existing drugs for difficult-to-treat diseases through a website, a smartphone, or other mobile device. In this episode, FDA’s Division of Drug Information interviews Ms. Heather Stone, FDA’s health science policy analyst in the FDA’s Office of Medical Policy, and Dr. Marco Schito, Executive Director of the Critical Path Institute’s CURE Drug Repurposing Collaboratory, or CDRC to discuss the benefits and future of CURE ID.


In this episode of Q&A with FDA, we hear from Dr. Marta Sokolowska, Deputy Center Director for Substance Use and Behavioral Health in FDA’s Center for Drug Evaluation and Research, discuss the Agency’s vision as it relates to encouraging harm reduction, including expanding availability and access to lifesaving overdose reversal products. Dr. Sokolowska delves into the impacts of the recent approvals of nonprescription naloxone nasal spray as well as prescription nalmefene nasal spray, another medication for opioid overdose.


In this podcast series, we answer some of the most frequently asked questions we’ve received from the public.